Inhibrx Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

InhibrxDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -37% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 37.9% pro Jahr.

Wichtige Informationen

-37.0%

Wachstumsrate der Gewinne

-15.3%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	-37.9%
Eigenkapitalrendite	-2,344.0%
Netto-Marge	-15,207.8%
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 23

Aufschlüsselung der Einnahmen und Ausgaben

Wie Inhibrx Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGM:INBX Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
31 Mar 24	2	-271	33
31 Dec 23	2	-241	29
30 Sep 23	0	-189	27
30 Jun 23	1	-172	24
31 Mar 23	1	-163	22
31 Dec 22	2	-145	21
30 Sep 22	5	-125	19
30 Jun 22	7	-111	17
31 Mar 22	7	-94	14
31 Dec 21	7	-82	12
30 Sep 21	7	-78	11
30 Jun 21	11	-78	10
31 Mar 21	13	-75	8
31 Dec 20	13	-76	7
30 Sep 20	10	-75	6
30 Jun 20	6	-74	6
31 Mar 20	6	-68	6
31 Dec 19	13	-51	6
30 Sep 19	15	-40	6
30 Jun 19	15	-30	6
31 Mar 19	14	-26	5
31 Dec 18	9	-31	5
30 Sep 18	7	-35	4
31 Dec 17	8	-19	3
31 Dec 16	7	-8	2

Qualität der Erträge: INBX ist derzeit unrentabel.

Wachsende Gewinnspanne: INBX ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: INBX ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 37% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von INBX verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: INBX ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: INBX hat eine negative Eigenkapitalrendite (-2344.01%), da es derzeit unrentabel ist.

Inhibrx Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Inhibrx Files Form 15

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Executive VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Price target decreased by 20% to US$35.50

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 308%, EPS downgraded

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx, Inc. announced that it has received $200.000633 million in funding

Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding

Consensus revenue estimates increase by 26%

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 85%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus forecasts updated

Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma

Consensus revenue estimates increase by 42%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105

Inhibrx: Potential To Move To Registration Study With INBRX-101

High number of new and inexperienced directors

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

Consensus revenue estimates fall by 17%

Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Price target decreased to US$49.67

Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program

Inhibrx, Inc., Annual General Meeting, May 25, 2022

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Price target decreased to US$49.67

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Inhibrx, Inc. Announces Initial Phase 1 Dose Escalation Results for INBRX-106

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.77 loss in 3Q 2020)

Price target increased to US$42.60

Second quarter 2021 earnings released: US$0.55 loss per share (vs US$0.98 loss in 2Q 2020)

Inhibrx, Inc.(NasdaqGM:INBX) dropped from Russell 3000E Value Index

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn